About ipilimumb vial
CTLA-4 immune checkpoint inhibitor
Used for
- Treats melanoma, sometimes with nivolumab.
- Treats kidney, lung, liver, and other cancers in selected patients.
Usual adult dose
Usually 3 mg/kg by IV infusion every three weeks for four doses; schedules vary by cancer and combination treatment.
Usual dose in children
For certain cancers, usually 3 mg/kg by IV infusion every three weeks for four doses; specialist-directed.
Common side effects
- Diarrhea, nausea, vomiting, or abdominal pain
- Skin rash or itching
- Fatigue
- Inflammation of the bowel, liver, lungs, or hormone glands
Important warnings
- Immune reactions can be severe, affect any organ, and occur during or after treatment.
- Prompt assessment is needed for new diarrhea, breathing problems, yellow skin, severe rash, or unusual weakness.
- Treatment requires specialist monitoring; corticosteroids or other immune-suppressing treatment may be needed.
- Use cautiously after organ transplant or with autoimmune disease.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception during treatment and for three months afterward are advised.
Breastfeeding
Avoid breastfeeding during treatment and for three months after the final dose.
Interactions
- Other immune checkpoint inhibitors can increase immune-related side effects.
- Systemic corticosteroids or other immune-suppressing medicines may affect treatment; use is specialist-directed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.